Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMILY N PRENDERGAST

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1780995803
CMS profile
670568
Location
MINNEAPOLIS, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,385.36

22 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $2,228.72 4
INTUITIVE SURGICAL, INC. $2,156.64 18

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMILY N PRENDERGAST

NPI 1780995803 · CMS profile ID 670568

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

MINNEAPOLIS, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780995803?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMILY N PRENDERGAST, NPI 1780995803, CMS profile ID 670568. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780995803?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EMILY N PRENDERGAST, NPI 1780995803, CMS profile ID 670568. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780995803?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EMILY N PRENDERGAST, NPI 1780995803, CMS profile ID 670568, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1780995803?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

22 matching records · $4,385.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 22 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–22 of 22.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
INTUITIVE SURGICAL, INC. $10.8012/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137080383 CMS
INTUITIVE SURGICAL, INC. $13.0612/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137085069 CMS
INTUITIVE SURGICAL, INC. $9.0712/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137090720 CMS
INTUITIVE SURGICAL, INC. $19.5412/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137114063 CMS
INTUITIVE SURGICAL, INC. $5.4012/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137121106 CMS
INTUITIVE SURGICAL, INC. $14.1012/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137134781 CMS
INTUITIVE SURGICAL, INC. $6.4112/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137142914 CMS
INTUITIVE SURGICAL, INC. $38.9312/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137158491 CMS
INTUITIVE SURGICAL, INC. $20.2912/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137224530 CMS
INTUITIVE SURGICAL, INC. $21.9312/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137211647 CMS
GlaxoSmithKline, LLC. $5.0811/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116677551 CMS
INTUITIVE SURGICAL, INC. $313.9310/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137153532 CMS
INTUITIVE SURGICAL, INC. $19.0010/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137193561 CMS
INTUITIVE SURGICAL, INC. $582.7010/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137208143 CMS
GlaxoSmithKline, LLC. $8.6510/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116368135 CMS
INTUITIVE SURGICAL, INC. $500.0007/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137128156 CMS
INTUITIVE SURGICAL, INC. $36.6706/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137079523 CMS
INTUITIVE SURGICAL, INC. $125.0006/04/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1156506872 CMS
GlaxoSmithKline, LLC. $2,175.0005/29/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116625468 CMS
GlaxoSmithKline, LLC. $39.9903/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116150582 CMS
INTUITIVE SURGICAL, INC. $389.8103/05/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137245172 CMS
INTUITIVE SURGICAL, INC. $30.0003/05/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137268746 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $1,800.00 1
PY2022 $120.00 1
PY2024 $4,385.36 22
PY2025 $3,304.08 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $40,059.40 13
PY2024 Principal investigator $34,813.04 7
PY2023 Principal investigator $305,678.61 18
PY2022 Principal investigator $385,361.71 71
PY2021 Principal investigator $620,544.15 127
PY2020 Principal investigator $1,117,220.38 160
PY2019 Principal investigator $1,317,552.79 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

127 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $1,374.00 12/31/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 809539886
Principal investigator 1 Merck Sharp & Dohme Corporation $20,235.44 12/31/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer KEYNOTE-A18 , ENGOT-cx11,GOG-3047 No dispute reported 06/30/2026 848749985
Principal investigator 1 Merck Sharp & Dohme Corporation $10,705.93 12/31/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 848755199
Principal investigator 1 Merck Sharp & Dohme Corporation $118,638.80 12/31/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 848755201
Principal investigator 1 GlaxoSmithKline, LLC. $565.25 12/15/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2,OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 809526935
Principal investigator 1 Merck Sharp & Dohme Corporation $5,285.00 12/15/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 848769413
Principal investigator 1 GlaxoSmithKline, LLC. $4,826.00 12/14/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809495607
Principal investigator 1 GlaxoSmithKline, LLC. $565.25 12/14/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2,OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 809526929
Principal investigator 1 Incyte Corporation $11.76 12/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148569
Principal investigator 1 Incyte Corporation $52.04 12/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148575
Principal investigator 1 GlaxoSmithKline, LLC. $9,576.00 11/09/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809495605
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 11/05/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 809501131
Principal investigator 1 GlaxoSmithKline, LLC. $406.09 11/04/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2,OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 809542453
Principal investigator 1 GlaxoSmithKline, LLC. $1,374.00 11/03/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 809501179
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 11/02/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809525317
Principal investigator 1 Clovis Oncology, Inc. $8,076.25 10/27/2021 Non-covered Recipient Entity
Health Partners Institute
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 796700107
Principal investigator 1 GlaxoSmithKline, LLC. $404.65 10/20/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2,OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 809507901
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 10/15/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2,OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 809542459
Principal investigator 1 GlaxoSmithKline, LLC. $16,338.00 10/13/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809504379
Principal investigator 1 GlaxoSmithKline, LLC. $5,679.00 10/13/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809504739
Principal investigator 1 Incyte Corporation $13.01 10/05/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148571
Principal investigator 1 Incyte Corporation $26.02 10/05/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148573
Principal investigator 1 Incyte Corporation $65.05 10/05/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148577
Principal investigator 1 Incyte Corporation $71.20 10/05/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148579
Principal investigator 1 Incyte Corporation $26.02 10/05/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148581
Principal investigator 1 Incyte Corporation $26.02 10/05/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148583
Principal investigator 1 Incyte Corporation $11.76 09/29/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148537
Principal investigator 1 Incyte Corporation $28.12 09/29/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148539
Principal investigator 1 Incyte Corporation $11.76 09/29/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148561
Principal investigator 1 Incyte Corporation $11.76 09/29/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148563
Principal investigator 1 Incyte Corporation $11.76 09/29/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148565
Principal investigator 1 Incyte Corporation $11.76 09/29/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148567
Principal investigator 1 Merck Sharp & Dohme Corporation $25,763.00 09/15/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 848769419
Principal investigator 1 GlaxoSmithKline, LLC. $62,469.00 09/14/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809495721
Principal investigator 1 GlaxoSmithKline, LLC. $20,300.00 09/08/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809504367
Principal investigator 1 GlaxoSmithKline, LLC. $6,149.00 08/17/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809525567
Principal investigator 1 Clovis Oncology, Inc. $38,740.00 08/10/2021 Non-covered Recipient Entity
Health Partners Institute
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 796700113
Principal investigator 1 Incyte Corporation $11.76 08/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148529
Principal investigator 1 Incyte Corporation $23.52 08/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148531
Principal investigator 1 Incyte Corporation $17.80 08/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148533
Principal investigator 1 Incyte Corporation $28.12 08/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148535
Principal investigator 1 Incyte Corporation $11.76 08/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148545
Principal investigator 1 Incyte Corporation $11.76 08/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148547
Principal investigator 1 Incyte Corporation $11.76 08/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148549
Principal investigator 1 Incyte Corporation $11.76 08/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148551
Principal investigator 1 Incyte Corporation $23.52 08/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148553
Principal investigator 1 Incyte Corporation $23.52 08/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148555
Principal investigator 1 Incyte Corporation $11.76 08/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148557
Principal investigator 1 Incyte Corporation $11.76 08/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148559
Principal investigator 1 GlaxoSmithKline, LLC. $7,035.00 07/20/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2,OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 809496941
Principal investigator 1 Incyte Corporation $11.76 07/19/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148521
Principal investigator 1 Incyte Corporation $47.40 07/19/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148523
Principal investigator 1 Incyte Corporation $102.30 07/19/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148525
Principal investigator 1 Incyte Corporation $17.80 07/19/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148527
Principal investigator 1 Incyte Corporation $11.76 07/19/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148541
Principal investigator 1 Incyte Corporation $11.76 07/19/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148543
Principal investigator 1 GlaxoSmithKline, LLC. $10,489.00 07/13/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809496499
Principal investigator 1 GlaxoSmithKline, LLC. $17,855.00 06/29/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809485949
Principal investigator 1 Incyte Corporation $23.52 06/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148501
Principal investigator 1 Incyte Corporation $35.28 06/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148503
Principal investigator 1 Incyte Corporation $28.12 06/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148505
Principal investigator 1 Incyte Corporation $23.52 06/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148507
Principal investigator 1 Incyte Corporation $35.28 06/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148509
Principal investigator 1 Incyte Corporation $35.28 06/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148511
Principal investigator 1 Incyte Corporation $35.28 06/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148513
Principal investigator 1 Incyte Corporation $23.52 06/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148515
Principal investigator 1 Incyte Corporation $35.28 06/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148517
Principal investigator 1 Incyte Corporation $23.52 06/02/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148519
Principal investigator 1 GlaxoSmithKline, LLC. $3,609.10 05/21/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2,OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 809542447
Principal investigator 1 GlaxoSmithKline, LLC. $14,537.00 05/04/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809483769
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 04/27/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809483649
Principal investigator 1 GlaxoSmithKline, LLC. $49,968.00 04/20/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809483767
Principal investigator 1 GlaxoSmithKline, LLC. $5,679.00 04/20/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809487673
Principal investigator 1 Incyte Corporation $23.52 04/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148499
Principal investigator 1 Clovis Oncology, Inc. $36,977.50 03/25/2021 Non-covered Recipient Entity
Health Partners Institute
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 796700111
Principal investigator 1 GlaxoSmithKline, LLC. $28,395.00 03/02/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809480401
Principal investigator 1 Incyte Corporation $35.60 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148401
Principal investigator 1 Incyte Corporation $20.30 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148403
Principal investigator 1 Incyte Corporation $30.00 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148405
Principal investigator 1 Incyte Corporation $78.50 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148407
Principal investigator 1 Incyte Corporation $2.10 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148409
Principal investigator 1 Incyte Corporation $56.24 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148411
Principal investigator 1 Incyte Corporation $85.25 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148413
Principal investigator 1 Incyte Corporation $68.50 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148415
Principal investigator 1 Incyte Corporation $79.00 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148417
Principal investigator 1 Incyte Corporation $47.04 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148423
Principal investigator 1 Incyte Corporation $47.04 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148425
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148427
Principal investigator 1 Incyte Corporation $11.76 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148429
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148431
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148433
Principal investigator 1 Incyte Corporation $11.76 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148435
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148437
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148439
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148441
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148443
Principal investigator 1 Incyte Corporation $11.76 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148445
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148447
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148449
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148451
Principal investigator 1 Incyte Corporation $11.76 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148453
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148455
Principal investigator 1 Incyte Corporation $35.60 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148457
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148459
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148461
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148463
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148465
Principal investigator 1 Incyte Corporation $11.76 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148467
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148469
Principal investigator 1 Incyte Corporation $35.60 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148471
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148473
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148475
Principal investigator 1 Incyte Corporation $11.76 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148477
Principal investigator 1 Incyte Corporation $23.52 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148479
Principal investigator 1 Incyte Corporation $56.24 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148481
Principal investigator 1 Incyte Corporation $85.25 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148483
Principal investigator 1 Incyte Corporation $78.50 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148485
Principal investigator 1 Incyte Corporation $17.80 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148487
Principal investigator 1 Incyte Corporation $2.10 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148489
Principal investigator 1 Incyte Corporation $20.30 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148491
Principal investigator 1 Incyte Corporation $30.00 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148493
Principal investigator 1 Incyte Corporation $68.50 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148495
Principal investigator 1 Incyte Corporation $79.00 03/01/2021 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 831148497
Principal investigator 1 GlaxoSmithKline, LLC. $34,802.00 02/17/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809483765
Principal investigator 1 GlaxoSmithKline, LLC. $6,804.00 01/12/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 809478409
Principal investigator 1 GlaxoSmithKline, LLC. $8,950.00 01/06/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 809481419
Principal investigator 1 Clovis Oncology, Inc. $31,456.25 01/04/2021 Non-covered Recipient Entity
Health Partners Institute
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 796700109